PROSTATIC NEOPLASMS

This early-stage study tests a drug called apalutamide in 19 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check how the drug moves through the body and to see if it is safe. Researchers will also me…

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants receive…

This early-stage study tests a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug is an antibody carrying a radioactive payload that targets a protein found on prostate cancer cells.…

This study offers apalutamide to men whose prostate cancer has stopped responding to hormone therapy but has not yet spread. The goal is to collect safety information until the drug becomes widely available. Participants must have rising PSA levels and continue their current horm…

This study looked at how two drugs, JNJ-56021927 and abiraterone acetate, interact in men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to check safety and find the right doses. Fifty-seven men took part, and the results help doctors under…

This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men with prostate cancer that has spread. About 1,145 men took part across 20 countries. The goal is to see if the combination delays cancer growth and improves surviva…

This study tests a drug called apalutamide in Chinese men with a type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread yet. The goal is to see if the drug can delay a rise in PSA levels, a key sign of cancer progression, compared to a p…

This study tested whether adding apalutamide to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 982 men who had not yet received chemotherapy took part. The goal was to see if the …

This study tests whether adding enzalutamide to standard hormone therapy and radiation can delay or prevent the spread of prostate cancer in men with high-risk localized disease. About 800 men will receive either standard treatment or standard treatment plus enzalutamide. The goa…

This study compares two common radiation therapy schedules for men with prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. The goal is to find which schedule works better at controlling the cancer and causes fewer side effects. About 400 men with early-stage prost…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug or a placebo alongside hormone therapy. The goal is…

This study looks at whether a 16-week home-based exercise program can slow prostate cancer in Black men who are monitoring their cancer without immediate treatment. About 68 men will take part. The program involves high-intensity interval training (HIIT) done virtually with a coa…

This early-stage study tests a new drug called JNJ-78278343 for men with advanced prostate cancer that has spread. The drug works by redirecting the body's immune T-cells to attack cancer cells. The main goals are to find the safest dose and check for side effects in 216 particip…

This study tests whether adding apalutamide to standard radiation and hormone therapy can delay cancer spread or death in men with high-risk prostate cancer that has not yet spread. About 692 participants are involved. The approach aims to better control the disease, but ongoing …

This study tests whether adding apalutamide to standard hormone therapy can delay cancer spread in men with high-risk prostate cancer who are also receiving radiation therapy. About 1,500 participants took either the drug combination or a placebo. The main goal is to see if the t…

This study looks at how well the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, in men with advanced prostate cancer that no longer responds to hormone therapy. About 136 men will take the drugs in different forms and sequences to…

This study tests a new treatment called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells. It is for men whose cancer has spread and stopped responding to hormone therapy, but who have not yet had chemotherapy. The study compares this new treatment to swi…

This study tests whether a new radioactive tracer called 18F-DCFPyL can better detect where prostate cancer has spread in the body compared to a standard tracer. About 96 adults with metastatic prostate cancer will receive both types of scans and be followed for one year. The goa…

This study looks at whether taking marine omega-3 fatty acids (found in fish oil) and a drug called dutasteride can stop low-risk prostate cancer from progressing. The 120 participants are men with low-grade prostate cancer who are under active surveillance. Researchers will meas…

This study was designed to test whether a 3-month supervised exercise program can improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have followed an individual training plan with a physiotherapist, and …

This study tests a personalized onco-sexology program designed to prevent and treat side effects of radical prostatectomy for localized prostate cancer. Researchers will compare sexual quality of life one year after surgery between 135 men who join the program and those who do no…

This study collects blood and saliva samples from people with cancer and their family members to build a DNA bank. Researchers will use these samples to study how genes may increase the risk of developing certain cancers. The goal is to better understand inherited cancer tendenci…

This research study aims to identify specific prostate cancer markers in blood samples from 40 prostate cancer patients and 20 healthy volunteers. Researchers will test commercial antibodies to see which ones can detect these markers in circulating tumor cells. The goal is to imp…

This study looks at whether a special MRI scan (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely avoid treatment and which need active therapy. About 200 men already on active surveillance will receive the scan. If the MRI finds suspicio…